BioCentury | Nov 14, 2020
Emerging Company Profile

Ex-Mavupharma execs reunite at Inipharm to build liver disease pipeline

Inipharm debuted Wednesday with $35 million in series A funding, a team of Mavupharma veterans and a small molecule portfolio targeting an enzyme that is upregulated across a handful of liver diseases. ...
BioCentury | Jul 19, 2019
Financial News

July 19 Financial Quick Takes: Amarin raises cash ahead of Vascepa PDUFA date, plus Atara, Sunstone and Forendo

...Vesalius Biocapital III Partners and M Ventures. Forendo's FOR-6219, an inhibitor of hydroxysteroid-17-beta dehydrogenase 1 (HSD17B1...
BioCentury | Feb 14, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: January 2019

New Therapeutic Targets and Biomarkers: January 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during January. Therapeutic targets are defined as any protein, gene or other molecule...
BioCentury | Jan 23, 2019
Distillery Therapeutics

Musculoskeletal

INDICATION: Bone repair Cell culture and mouse studies identified a bicyclic HSD17B2 inhibitor that could help treat bone fractures. Chemical synthesis and testing in enzyme activity assays of bicyclic hydroxyphenylmethanone analogs yielded a compound that...
BioCentury | Apr 4, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: March 2018

New Therapeutic Targets and Biomarkers: March 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during March 2018. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Mar 23, 2018
Company News

Regeneron IDs gene variant tied to NASH, partners with Alnylam

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) partnered with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) to develop RNAi therapeutics that target the hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) gene to treat non-alcoholic steatohepatitis. In a paper published March 21 in the...
BioCentury | Mar 21, 2018
Company News

Regeneron IDs gene variant tied to NASH, partners with Alnylam

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) partnered with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) to develop RNAi therapeutics that target the hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) gene to treat non-alcoholic steatohepatitis. In a paper published Wednesday in the New...
BioCentury | May 3, 2017
Distillery Therapeutics

Cancer

...INDICATION: Breast cancer In vitro and cell-based studies identified a dual STS / HSD17B1 inhibitor that...
...and in vitro testing of aryl sulfamate analogs identified a compound that inhibited STS and HSD17B1...
...nM, respectively. In breast cancer cell line-based enzymatic activity assays, the compound inhibited STS and HSD17B1...
BioCentury | Oct 23, 2014
Financial News

Forendo closes EUR 12M series A

...HSD17B1 ) inhibitor, through proof-of-concept testing to treat endometriosis. The company acquired a portfolio of HSD17B1...
BioCentury | Dec 19, 2013
Translation in Brief

Translational tidbits

...to treat endometriosis and estrogen-dependent cancers, with a focus on preclinical hydroxysteroid 17b dehydrogenase 1 (HSD17B1...
Items per page:
1 - 10 of 14